A uniqe antilipidemic drug - Probucol

Journal of Atherosclerosis and Thrombosis

Volumn 15, Issue 6, 2008, Pages 304-305

  Yamamoto, Akira ^a,b  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b Health Care Facilities for the Aged   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROBUCOL; SCAVENGER RECEPTOR BI; ANTIOXIDANT; BILE ACID; DRUG; HYPOCHOLESTEROLEMIC AGENT; LIPID;

ABSENCE OF SIDE EFFECTS; ANTIOXIDANT ACTIVITY; APHERESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; EDITORIAL; FAMILIAL HYPERCHOLESTEROLEMIA; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; NONHUMAN; OXIDATIVE STRESS; QT INTERVAL; RESTENOSIS; RISK REDUCTION; SECONDARY PREVENTION; XANTHOMA; CELL LINE; CHEMISTRY; HOMOZYGOTE; METABOLISM; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; ATHEROSCLEROSIS; BILE ACIDS AND SALTS; CELL LINE; CHOLESTEROL, HDL; HOMOZYGOTE; HUMANS; LIPIDS; PHARMACEUTICAL PREPARATIONS; PROBUCOL; RISK FACTORS;

EID: 59149101633     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E621     Document Type: Editorial

References (22)

1. Heel RC, Brogden RN, Speight TM, Avery GS: Probucol: a review of its pharmacological properties and therapeutic use in patients with hypercholesterolemia. Drugs, 1978; 15:409-428
2. Buckley MM, Goa KL, Price AH, Brogden RN: Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs, 1989; 37:761-800
3. Baker SG, Joffe BI, Mendelsohn D, Seftel HC: Treatment of homozygous familial hypercholesterolaemia with probucol. S Afr Med J, 1982; 62:7-11
4. Yamamoto A, Matsuzawa Y, Kishino B, Hayashi R, Hirobe K, Kikkawa T: Effects of probucol on homozygous cases of familial hypercholesterolemia. Atherosclerosis, 1983; 48:157-166
5. Buxtorf JC, Jacotot B, Beaumont V, and Beaumont JL: Action du probucol dans les hypercholestérolémies familiales de Type II. Semaine des Hôpiteaux Paris, 1985; 61:837-840
6. Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D: Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest, 1986; 77:641-644
7. Yamamoto A, Hara H, Takaichi S, Wakasugi J, Tomikawa M: Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesions. Am J Cardiol, 1988; 62:31B-36B
8. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol, modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med, 1989; 320:915-924
9. Walldius G, Erikson U, Olsson AG, Bergstrand L, Hådell K, Johansson J, Kaijser L, Lassvik C, Mölgaard J, Nilsson S, Schafer-Elinder L, Stenport G, Holme I: The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol, 1994; 74:875-883
10. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F: Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol, 1997; 17:1114-1120
11. Krieger M, Kozarsky K: Influence of the HDL receptor SR-B1 on atherosclerosis. Curr Opin Lipidol 1999; 10:491-497
12. Schwartz CC, Halloran LG, Vlahcevic ZR, Gregory DH, Swell L: Preferential utilization of free cholesterol from high-density lipoproteins for biliary cholesterol secretion in man. Science, 1978; 200:62-64
13. Carey MC: Homing-in on the origin of biliary steroids. Gut, 1997; 41:721-722
14. Tall AR, Small DM: Body cholesterol removal: role of plasma high-density lipoproteins. Adv Lipid Res, 1980, 17:1-51
15. Arai T, Wang N, Bezouevski M, Welch C, Tall AR: Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor B1 transgene. J Biol Chem, 1999; 274:2366-2371
16. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Datta G, Garber DW, Fogelman AM: Apolipoprotein A-1 mimetic peptides. Arterioscler Thromb Vasc Biol, 2005; 25:1325-1331
17. Singla DK, Kaur K, Sharma AK, Dhingra S, Singal PK: Probucol promotes endogenous antioxidant reserve and confers protection against reperfusion injury. Can J Physiol Pharmacol, 2007; 85:439-443
18. Tanous D, Bräsen JH, Choy K, Wu BJ, Kathir K, Lau A, Celermajer DS, Stocker R: Probucol inhibits in-stent thrombosis and neointimal hyperplasia by promoting re-endothelialization. Atherosclerosis, 2006; 189:342-349
19. Yang YB, Yang YX, Su B, Tang YL, Zhu BY, Hu ZW, Li GY, Li YJ, Liao DF: Probucol mediates vascular remodeling after percutaneous transluminal angioplasty via down-regulation of the ERK1/2 signaling pathway. Eur J Pharmacol, 2007; 570:125-134
20. Merat S, Malekzadeh R, Sohrabi MR, Hormazdi M, Naserimoghadam S, Mikaeli J, Farahvash MJ, Ansari R, Sotoudehmanesh R, Khatibian M: Probucol in the treatment of nonalcoholic steatohepatitis: an open-labeled study. J Clin Gastroenterol, 2003; 36:266-268
21. Kawaguchi A, Yutani C, Yamamoto A: Hypercholesterolemic valvulopathy: an aspect of malignant atherosclerosis. Ther Apher Dial, 2003; 7:439-443
22. Rossebøo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecg W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R; SEAS Investigators: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med, 2008; 359:1343-1356